Natco Pharma Share Price Target 2025, 2026, 2030, 2040, 2050
Natco Pharma is an Indian company based in Hyderabad. It started in 1981 and makes different types of drugs for cancer, heart problems, and diabetes. The company sells medicines in India and other countries like Canada, Brazil, and the USA. Natco also makes unique raw materials, such as active pharmaceutical ingredients (API), which are used to make medicines.
This blog will provide the details of Natco Pharma Share Price targets as far as 25 years from now (2025 – 2050) based on its fundamentals, market position, and growth potential.
What is Natco Pharma Ltd NSE: NATCOPHARM ?
Natco Pharma focuses on making challenging and rare medicines that other companies don’t easily make. It makes cancer medicines and exports them to many countries. The company also started making agricultural products like pesticides. Natco spends much on research to create new drugs and improve its products.
Fundamental Data
| Parameter | Value |
|---|---|
| Market Cap | ₹14,721 Cr. |
| High / Low | ₹1,639 / 776 |
| Stock P/E | 7.90 |
| Industry P/E | 29.4 |
| Book Value | ₹399 |
| Price to Book Value | 2.06 |
| Dividend Yield | 1.16% |
| ROCE | 30.1% |
| ROE | 25.9% |
| EPS | ₹104 |
| Promoter Holding | 49.6% |
| Debt | ₹208 Cr. |
| Debt to Equity | 0.03 |
| Net Profit | ₹1,864 Cr. |
| PBT Ann | ₹1,674 Cr. |
| Net Cash Flow (PY) | ₹20.8 Cr. |
| Current Liabilities | ₹1,009 Cr. |
| Current Assets | ₹5,002 Cr. |
| Dividend Last Year | ₹170 Cr. |
| PEG Ratio | 0.46 |
| Graham Number | ₹967 |
Peer Comparisons
| S.No. | Name | P/E | Market Cap Rs.Cr. | Div Yld % | NP Qtr Rs.Cr. | Qtr Profit Var % | Sales Qtr Rs.Cr. | Qtr Sales Var % | ROCE % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Sun Pharma.Inds. | 32.83 | 387156.69 | 0.84 | 2912.98 | 22.66 | 13675.46 | 10.46 | 17.32 |
| 2 | Cipla | 23.73 | 118182.20 | 0.89 | 1574.59 | 31.37 | 7072.97 | 7.10 | 22.80 |
| 3 | Mankind Pharma | 49.97 | 96630.02 | 0.00 | 416.38 | -10.01 | 2396.57 | 8.48 | 24.57 |
| 4 | Dr Reddy’s Labs | 17.56 | 94137.81 | 0.71 | 1404.20 | 1.69 | 8381.20 | 15.81 | 26.53 |
| 5 | Zydus Lifesci. | 19.60 | 88845.43 | 0.34 | 1026.20 | 33.34 | 5269.10 | 16.96 | 22.34 |
| 6 | Lupin | 30.22 | 86694.87 | 0.42 | 858.86 | 39.48 | 5767.71 | 10.97 | 15.72 |
| 7 | Aurobindo Pharma | 17.83 | 63342.89 | 0.42 | 845.57 | -9.69 | 7978.52 | 8.53 | 14.10 |
| 8 | Natco Pharma | 7.90 | 14721.04 | 1.16 | 132.40 | -37.75 | 474.80 | -37.41 | 30.10 |
| Period | Share Price (INR) |
|---|---|
| Before 1 Year | ₹983.50 |
| Before 6 Months | ₹1537 |
| Before 5 Years | ₹601 |
| All-Time Max | ₹1639 |
The company’s business will grow because it makes cancer and special medicines, which are always in demand. It sells medication in India and other countries like Canada and Brazil. The company also makes raw materials (API), which can help increase the share price target. The price may fluctuate tomorrow, but the long-term growth potential remains strong.
| Day | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| Tomorrow | -40 from today’s price | +78 from today’s price |
NATCOPHARM Indicator Based Technical Analysis
NOTE!
Signals may differ across timeframes. If you’re planning to purchase NATCOPHARM and keep it for more than one week, it’s suggested that you choose signals from weekly and daily timeframes. For trading in the short term, signals that range from 5 minutes to 1-hour timeframes are better appropriate.
The company is a well-known name in the pharmaceutical industry. It has a strong business in oncology products, generic medicines, and APIs. It is expanding its reach in both Indian and international markets. With new drugs and focusing on niche therapeutic segments, the company will likely show good growth in 2025.
Our analysis shows that the share price is expected to be between Rs 550 and Rs 1,375.
| Year | Minimum Price (₹) | Maximum Price (₹) |
|---|---|---|
| 2025 | 550 | 1375 |
| Month | Minimum Price (₹) | Maximum Price (₹) |
|---|---|---|
| January | 550 | 900 |
| February | 600 | 950 |
| March | 650 | 1000 |
| April | 700 | 1050 |
| May | 750 | 1100 |
| June | 800 | 1150 |
| July | 850 | 1200 |
| August | 900 | 1250 |
| September | 1000 | 1300 |
| October | 1100 | 1350 |
| November | 1200 | 1370 |
| December | 1250 | 1375 |
The company is strengthening its position in Cardiology, diabetes Products, and Hepatitis C Medicine HEPCINAT. Its international business in Canada and Brazil is performing well. With a research-based approach and contract manufacturing, The company will likely show good growth in 2026.
Our analysis shows that the share price is expected to be between Rs 975 and Rs 1,780.
| Year | Minimum Price (₹) | Maximum Price (₹) |
|---|---|---|
| 2026 | 975 | 1780 |
| Month | Minimum Price (₹) | Maximum Price (₹) |
|---|---|---|
| January | 975 | 1200 |
| February | 1050 | 1300 |
| March | 1100 | 1400 |
| April | 1150 | 1450 |
| May | 1200 | 1500 |
| June | 1250 | 1550 |
| July | 1300 | 1600 |
| August | 1350 | 1650 |
| September | 1400 | 1700 |
| October | 1500 | 1750 |
| November | 1600 | 1770 |
| December | 1700 | 1780 |
The company’s API Business and oncology segments will grow faster by 2030. The company is working on high-barrier-to-entry products and expanding into new foreign markets. With constant innovation and new partnerships, the company will likely show good growth in 2030.
Our analysis shows that the share price is expected to be between Rs 3,215 and Rs 4,300.
| Year | Minimum Price (₹) | Maximum Price (₹) |
|---|---|---|
| 2030 | 3215 | 4300 |
| Month | Minimum Price (₹) | Maximum Price (₹) |
|---|---|---|
| January | 3215 | 3500 |
| February | 3300 | 3600 |
| March | 3400 | 3700 |
| April | 3500 | 3800 |
| May | 3600 | 3900 |
| June | 3700 | 4000 |
| July | 3800 | 4100 |
| August | 3900 | 4150 |
| September | 4000 | 4200 |
| October | 4100 | 4250 |
| November | 4200 | 4280 |
| December | 4250 | 4300 |
By 2040, the company’s Generic Medicines and niche therapies will be more significant. Its Natcofarma Do Brasil joint venture and heavy R&D investments will help the company grow globally, which could push it to new heights.
Our analysis shows that the share price is expected to be between Rs 7,650 and Rs 8,975.
| Year | Minimum Price (₹) | Maximum Price (₹) |
|---|---|---|
| 2040 | 7650 | 8975 |
| Month | Minimum Price (₹) | Maximum Price (₹) |
|---|---|---|
| January | 7650 | 8000 |
| February | 7800 | 8200 |
| March | 7950 | 8350 |
| April | 8100 | 8500 |
| May | 8250 | 8600 |
| June | 8400 | 8700 |
| July | 8500 | 8750 |
| August | 8600 | 8800 |
| September | 8700 | 8850 |
| October | 8750 | 8900 |
| November | 8800 | 8950 |
| December | 8850 | 8975 |
With years of experience and technological advancements, The company is expected to become a global leader by 2050. Its business expansion, innovative medicines, and foreign investors’ interest could boost Its share price target to 2050, making it a valuable stock for long-term investors.
Our analysis shows that the share price is expected to be between Rs12,6005 and Rs 13,950.
| Year | Minimum Price (₹) | Maximum Price (₹) |
|---|---|---|
| 2050 | 12600 | 13950 |
| Month | Minimum Price (₹) | Maximum Price (₹) |
|---|---|---|
| January | 12600 | 12800 |
| February | 12850 | 13000 |
| March | 13050 | 13200 |
| April | 13250 | 13350 |
| May | 13400 | 13500 |
| June | 13550 | 13600 |
| July | 13650 | 13700 |
| August | 13750 | 13800 |
| September | 13800 | 13850 |
| October | 13850 | 13900 |
| November | 13900 | 13925 |
| December | 13925 | 13950 |
| Year | Minimum Price (₹) | Maximum Price (₹) |
|---|---|---|
| 2025 | 550 | 1375 |
| 2026 | 975 | 1780 |
| 2030 | 3215 | 4300 |
| 2040 | 7650 | 8975 |
| 2050 | 12600 | 13950 |
| Category | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|
| Promoters | 49.62% | 49.62% | 49.71% | 49.71% |
| FIIs | 17.94% | 17.51% | 17.45% | 16.14% |
| DIIs | 5.59% | 6.75% | 7.86% | 9.69% |
| Public | 26.88% | 26.13% | 24.99% | 24.46% |
Piramal Pharma Share Price Target 2025, 2026, 2030, 2040, 2050
Should I Buy Natco Pharma Stock?
The company’s shareholding pattern shows 49.62% with promoters, which means strong trust in the company. FIIs are increasing, showing interest from big investors. DIIs have slightly reduced their share. If you’re thinking long-term, the stock looks suitable for investment.
Natco Pharma Ltd Earning Results (Financials)
| Metric | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
| Sales | 4277 | 3999 | 2707 | 1945 | 2052 |
| Expenses | 2132 | 2245 | 1772 | 1681 | 1446 |
| Operating Profit | 2145 | 1754 | 936 | 264 | 606 |
| OPM % | 50% | 44% | 35% | 14% | 30% |
| Other Income | 330 | 126 | 105 | 99 | 104 |
| Interest | 20 | 19 | 14 | 18 | 13 |
| Depreciation | 192 | 187 | 164 | 143 | 117 |
| Profit Before Tax | 2263 | 1674 | 862 | 202 | 580 |
| Tax % | 17% | 17% | 17% | 16% | 24% |
| Net Profit | 1864 | 1388 | 715 | 170 | 442 |
| EPS (Rs) | 104.13 | 77.51 | 39.18 | 9.31 | 24.18 |
| Dividend Payout % | 12% | 12% | 14% | 48% | 22% |
Expert Forecasts On The Future Of Natco Pharma Ltd.
The company’s profit grows yearly, showing the company earns good money. The operating profit margin is now 50%, which means the company is making more profit from sales. If this growth continues, the company’s future will look very strong for long-term investment.
Is Natco Pharma Stock Good to Buy? (Bull case & Bear case)
Bullish Case:
- Strong profit growth every year
- High promoter holding (49.62%)
- Global business in pharma and API
- Future demand for cancer and specialty medicines
Bearish Case:
- High competition in pharma market
- Dependency on limited products
- Slow growth in domestic business
Conclusion
The company makes cancer and specialty medicines and earns from API and international business. Its stock may go up and down in the short term, but new drugs and business growth can give good returns in the long term. If you’re considering an investment, you should read the full article for details about the company’s performance and future stock projections.
Alembic Share Price Target 2025, 2026, 2030, 2040, 2050
